Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9FKSM)

Drug Name
4-(1H-indol-3-yl)-1-morpholinobutan-1-one Drug Info
Synonyms
CHEMBL395709; 4-(1H-indol-3-yl)-1-(morpholin-4-yl)butan-1-one; AC1LDAKL; 4-(1H-indol-3-yl)-1-morpholinobutan-1-one; Oprea1_287687; MLS000073378; SCHEMBL14882056; MolPort-001-888-170; ZINC280650; HMS2314G24; BDBM50207035; STK110153; AKOS000614077; MCULE-8725603794; SMR000013452; 313532-54-6; ST50900693; 4-indol-3-yl-1-morpholin-4-ylbutan-1-one; 4-(1H-indol-3-yl)-1-morpholin-4-ylbutan-1-one; SR-01000362492; 4-(1H-Indol-3-yl)-1-morpholin-4-yl-butan-1-one; SR-01000362492-1
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
645040
TTD Drug ID
DM9FKSM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [2]
Diethylcarbamazine DM1TJ8F Elephantiasis Approved [3]
Silymarin DMXBYQR N. A. N. A. Phase 4 [4]
3,4-Dihydroxycinnamic Acid DMVZL26 Thrombocytopenia 3B64 Phase 4 [5]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [6]
ABT-761 DM3FIC2 Asthma CA23 Phase 3 [7]
Tenidap DMHQRYE Rheumatoid arthritis FA20 Phase 3 [8]
FPL-62064 DMGF8MZ Inflammation 1A00-CA43.1 Phase 3 [9]
Flobufen DMPSG4D Rheumatoid arthritis FA20 Phase 3 [10]
Darbufelone DMYVKM5 Asthma CA23 Phase 2/3 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Arachidonate 5-lipoxygenase (5-LOX) TT2J34L LOX5_HUMAN Inhibitor [1]

References

1 Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem Lett. 2007 May 1;17(9):2414-20.
2 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
3 Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
4 Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
5 Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
6 Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
7 Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
8 The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
9 FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
10 Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
11 Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.